The estimated Net Worth of Mary Theresa Coelho is at least $1.3 million dollars as of 29 January 2021. Ms. Coelho owns over 10,190 units of Biodelivery Sciences International stock worth over $190,502 and over the last 7 years she sold BDSI stock worth over $0. In addition, she makes $1,104,960 as Chief Financial Officer et Treasurer at Biodelivery Sciences International.
Mary has made over 3 trades of the Biodelivery Sciences International stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 10,190 units of BDSI stock worth $56,962 on 29 January 2021.
The largest trade she's ever made was exercising 54,036 units of Biodelivery Sciences International stock on 15 January 2020 worth over $132,929. On average, Mary trades about 6,351 units every 29 days since 2018. As of 29 January 2021 she still owns at least 34,079 units of Biodelivery Sciences International stock.
You can see the complete history of Ms. Coelho stock trades at the bottom of the page.
Mary Theresa Coelho serves as Chief Financial Officer, Treasurer of the Company. Ms. Coelho’s extensive experience includes serving in diverse leadership capacities across various industries for both private and public global companies. Prior to joining the company, Ms. Coelho served as Chief Financial Officer and Treasurer at Balchem Corporation from October 2017 to October 2018. From September 2017 to October 2017, she served as Chief Operating Officer for Diversey, Inc., a multi-billion dollar global private equity carve-out from Sealed Air Corporation and held senior finance positions at Diversey Care from October 2014 through August 2017, including as Chief Financial Officer for Diversey Care. Ms. Coelho has also served in senior finance leadership roles at Novartis from 2007 to 2014. She spent the previous twenty years at Mars, Incorporated where she held roles of increasing responsibility and encompassing leadership across all areas of finance and general management. Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and a Bachelor of Arts degree in both Economics and International Relations, summa cum laude, from The American University School of International Service.
As the Chief Financial Officer et Treasurer of Biodelivery Sciences International, the total compensation of Mary Coelho at Biodelivery Sciences International is $1,104,960. There are 1 executives at Biodelivery Sciences International getting paid more, with Scott Plesha having the highest compensation of $1,503,860.
Mary Coelho is 58, she's been the Chief Financial Officer et Treasurer of Biodelivery Sciences International since 2019. There are 5 older and 8 younger executives at Biodelivery Sciences International. The oldest executive at Biodelivery Sciences International is William Watson, 69, who is the Independent Director.
Mary's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10018.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott et Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: